ARTICLE | Company News
Ambrx, MabSpace deal
January 6, 2017 10:05 PM UTC
Ambrx and MabSpace partnered exclusively to discover and develop oncology antibody drug conjugates (ADCs). The partners will use MabSpace's humanized antibody technology in combination with Ambrx's EuCode conjugation platform. The partners said they will share costs and rights to resulting products in the global collaboration. MabSpace said the deal includes an option to renegotiate once development costs become "significant, e.g., Phase III." ...